Form 4: Iovance Biotherapeutics Executive Reports Stock Transaction
Insider Transaction (Form 4)
Daniel Gordon Kirby, Chief Commercial Officer of Iovance Biotherapeutics, Inc., reported multiple transactions in common stock on August 10, 2026.
Summary
- Option exercise/conversion: acquired 10,001 Common Stock on August 10, 2026; holds 156,947 after (Direct).
- Tax/exercise-price withholding: disposed of 2,436 Common Stock at $6.40 ($15,590) on August 10, 2026; holds 154,511 after (Direct).
- Option exercise/conversion: disposed of 10,001 Restricted Stock Units on August 10, 2026; holds 60,003 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Daniel Gordon Kirby — Officer (Chief Commercial Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-10 | Option exercise/conversion | Common Stock | 10,001 | — | — | 156,947 |
| 2026-08-10 | Tax/exercise-price withholding | Common Stock | 2,436 | $6 | $15.6K | 154,511 |
| 2026-08-10 | Option exercise/conversion | Restricted Stock Units | 10,001 | — | — | 60,003 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-10 | Option exercise/conversion (10,001 shares) |
| 2026-08-10 | Tax/exercise-price withholding (2,436 shares) |
| 2026-08-10 | Option exercise/conversion (10,001 shares) |
Keywords
insider transaction, Form 4, IOVA, IOVANCE BIOTHERAPEUTICS, INC., neutral, Daniel Gordon Kirby
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.